10-Q: Evolent Health Reports Q2 Loss Amid Revenue Decline & Debt Restructuring

Evolent Health, Inc. reported a significant revenue decrease and increased net loss for Q2 2025, driven by customer contract changes and higher medical claims costs, while actively restructuring its debt.

Summary

• Revenue for the three months ended June 30, 2025, decreased by $202.8 million (31.3%) to $444.3 million, compared to $647.1 million in the prior year.
• Net loss attributable to common shareholders for Q2 2025 increased to $51.1 million, up from $6.4 million in Q2 2024.
• Operating income shifted to a loss of $1.2 million in Q2 2025, from an income of $7.8 million in Q2 2024.
• Cost of revenue decreased by $196.4 million (36.3%) to $343.9 million in Q2 2025, primarily due to lower claims costs from customer transitions and scope narrowing, but increased as a percentage of revenue due to business mix shift.
• Selling, general and administrative expenses increased by $6.0 million (8.7%) to $75.2 million in Q2 2025, driven by higher personnel costs, partially offset by lower stock compensation and lease expenses.
• Cash flows used in operating activities were $25.8 million for the six months ended June 30, 2025, a significant shift from $26.3 million provided in the same period of 2024, primarily due to $67.5 million in payments for prior-year performance suite contract reconciliations.
• Cash flows used in investing activities increased to $73.6 million for the six months ended June 30, 2025, mainly due to $56.0 million for asset acquisitions and business combinations, and $17.4 million for internal-use software and property/equipment purchases.
• Cash flows provided by financing activities were $98.9 million for the six months ended June 30, 2025, primarily from $221.0 million in Term Loan Facility borrowings, offset by $62.5 million in Revolving Facility repayments and $44.8 million in claims processing working capital changes.
• The company completed the exchange of its Series A Preferred Shares for a new $175.0 million second lien term loan facility on August 7, 2025, resulting in a $9.0 million extinguishment charge in Q2 2025.
• A $52.5 million loss on option exercise was recorded in Q2 2025 due to the purchase of a portion of an equity method investment for $51.5 million, related to oncology clinics that will cease operations.

Sentiment

Score: 3

Explanation: The company experienced significant revenue decline and increased net losses, with operating cash flow turning negative. While strategic debt restructuring and acquisitions are underway, the immediate financial performance is concerning, reflecting industry headwinds and one-time charges.

Positives

• Cost of revenue as a percentage of total revenue decreased from 83.5% in Q2 2024 to 77.4% in Q2 2025, indicating a shift towards higher margin product types.
• The company secured a commitment letter for an Incremental Facility of up to $150.0 million to retire 2025 Notes and for working capital, providing financial flexibility.
• The exchange of Series A Preferred Shares for a new second lien term loan facility simplifies the capital structure by converting preferred equity to debt with no common stock conversion feature.

Negatives

• Total revenue decreased significantly by 31.3% in Q2 2025 compared to Q2 2024, primarily due to contractual updates, customer transitions, and scope narrowing in the Performance Suite.
• Net loss attributable to common shareholders increased substantially from $6.4 million in Q2 2024 to $51.1 million in Q2 2025.
• Operating income turned into a loss of $1.2 million in Q2 2025, down from a $7.8 million income in the prior year.
• Cash flows from operating activities shifted from a positive $26.3 million in H1 2024 to a negative $25.8 million in H1 2025, largely due to payments for prior-year contract reconciliations.
• A significant $52.5 million loss was incurred on the purchase of an equity method investment, leading to the cessation of operations for the related oncology clinics.
• Interest expense increased from $6.0 million in Q2 2024 to $11.6 million in Q2 2025 due to new debt borrowings.

Risks

• Significant portion of revenue derived from a small number of largest partners, with potential material adverse effects from loss, termination, or renegotiation of these relationships.
• Increasing number of risk-sharing arrangements with partners introduces financial exposure.
• Growth and success of partners and certain revenues are difficult to predict and subject to external factors like governmental funding reductions.
• Ability to accurately predict exposure under performance-based contracts is a challenge.
• Failure by customers to provide accurate and timely information could impact operations.
• Ability to recover upfront costs in partner relationships and develop them over time is uncertain.
• Ability to attract new partners and capture new opportunities is crucial for growth.
• Maintaining and enhancing reputation and brand recognition is vital.
• Dependency on key personnel and ability to attract, hire, integrate, and retain them.
• Risks related to completed and future acquisitions, investments, alliances, and joint ventures, which could divert resources, result in unanticipated costs, or dilute stockholders.
• Ability to effectively manage growth and maintain an efficient cost structure.
• Exclusivity provisions in contracts may limit ability to partner with other providers.
• Risks related to managing offshore operations and achieving cost reduction goals.
• Ability to estimate target market size for services.
• Competition in the healthcare industry could limit market share expansion.
• Risks related to audits by CMS and other governmental payers, including whistleblower claims under the False Claims Act.
• Evolution of healthcare regulatory and political framework poses ongoing challenges.
• Restrictions on access to personal data and penalties from privacy and data protection laws.
• Data loss or corruption due to system failures or service disruptions at data centers.
• Liabilities and reputational risks related to safeguarding confidential data security and privacy.
• Ability to obtain, maintain, and enforce intellectual property rights and protect trademarks/trade names from infringement claims.
• Ability to protect the confidentiality of trade secrets.
• Risks associated with the use of artificial intelligence (AI) and machine learning models.
• Reliance on open-source software.
• Reliance on third parties and licensed technologies.
• Restrictions on ability to use, disclose, de-identify, or license data and integrate third-party technologies.
• Reliance on Internet infrastructure, bandwidth providers, data center providers, and internal systems.
• Potential for future material weaknesses in internal control over financial reporting, impacting timely and accurate financial statements.
• Ability to achieve future profitability.
• Impact of additional goodwill and intangible asset impairments on results of operations.
• Obligations to make material payments to pre-IPO investors for tax benefits, which may be accelerated or exceed realized benefits.
• Inability to obtain financing may reduce stockholder ownership.
• Conditional conversion features and accounting treatment changes of 2025 and 2029 Notes may adversely affect financial condition.
• Ability to raise funds for cash settlements of note conversions, repurchases, or redemptions.
• Interest rate risk and restrictive covenants under First Lien Credit Agreement and Second Lien Credit Agreement.
• Interference with ability to access credit facilities.
• Potential volatility of Class A common stock price.
• Provisions in certificate of incorporation and by-laws, and Delaware law, that discourage strategic transactions.
• Provisions in certificate of incorporation limiting stockholders' ability to obtain a favorable judicial forum.
• Intention not to pay cash dividends on Class A common stock.
• Impact of litigation proceedings, government inquiries, reviews, audits, or investigations.
• Risks related to bank failures where funds are deposited.
• Impact of public health emergencies, epidemics, pandemics, or contagious diseases.
• Cost of compliance with sustainability or other environmental, social responsibility, or governance laws and regulations.
• Impact of increasing inflationary pressures and rising consumer costs on the business.

Future Outlook

The company anticipates continued growth in the cost of treatment for cancer and cardiovascular patients over time, which is expected to be offset by contractual protections within its Performance Suite and the impact of its clinical interventions. The company is currently evaluating the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements, which amends U.S. tax law related to research and development and interest expense. The company is considering other financing sources to optimize its capital structure and support recent acceleration in organic new revenue bookings forecast for 2026 go-lives.

Management Comments

• We believe adherence to evidence-based clinical pathways supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.
• We are unable to predict how these broader dynamics will impact our business and results of operations in the future, but they could continue to impact our financial condition and results of operations and such future impacts could be material.
• We do not believe these impacts were material to our revenues or net loss for the three and six months ended June 30, 2025, respectively. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.
• We believe our current cash and cash equivalents and undrawn Revolving Facility will be sufficient to meet our working capital and capital expenditure requirements for at least the next twelve months as of the date the financial statements were issued.

Industry Context

The healthcare industry is experiencing a significant and fast-growing portion of costs related to specialty care, driven by new therapies and treatments. Evolent Health aims to address these rising costs through an integrated approach using technology and evidence-based clinical pathways. The company notes that medical claims costs in its Performance Suite grew faster than historical norms in 2024 and H1 2025, which is believed to be an industry-wide trend, impacting financial results. Medicaid redeterminations and certain customers exiting Medicaid Advantage operations also affected revenue, reflecting broader market dynamics in government-sponsored health programs.

Comparison to Industry Standards

• The company's observation of faster-than-historical growth in medical claims costs in its Performance Suite, which is believed to be industry-wide, suggests that Evolent Health is experiencing similar cost pressures as other market participants in the healthcare sector.
• The company's strategy to offset rising treatment costs through contractual protections and clinical interventions aligns with broader industry efforts to manage value-based care arrangements and control specialty care expenditures, similar to initiatives seen in other integrated delivery systems and health plans like UPMC, which was a founder of Evolent Health.

Corporate Governance

Legal Proceedings

• A shareholder derivative action filed on June 8, 2021, alleging negligent oversight of the company's relationship with University Healthcare, Inc. d/b/a Passport Health Plan, was dismissed on January 5, 2023.
• A shareholder demand letter sent on April 6, 2023, requesting investigation and litigation for breach of fiduciary duty against individuals named in the derivative action, was refused by the Board on February 15, 2024. The company cannot currently estimate the loss or range of possible losses related to this request.

Related Party Transactions

• The company had an economic relationship with an entity whose President and CEO was a Board member until February 2024, which accounted for the majority of related party revenue and cost of revenue for Q1 2024.
• The company holds economic interests in several entities accounted for under the equity method, providing management, operational, and support services to them. Revenue from these agreements was $1.0 million in Q2 2025 and $4.4 million in H1 2025.
• Accounts receivable from related parties were $6.3 million as of June 30, 2025, and accounts payable to related parties were $0.4 million.

Stakeholder Impact

• Shareholders: Experienced significant net loss and diluted EPS, but the debt restructuring aims to optimize capital structure. Potential for future dilution if capital is raised via equity.
• Creditors/Lenders: New second lien term loan facility and amendments to First Lien Credit Agreement redefine debt terms and covenants, impacting their risk exposure and repayment priorities.
• Customers: Contractual updates and scope narrowing with certain customers led to revenue decline, indicating shifts in service agreements and potentially impacting customer relationships.
• Employees: Higher personnel costs were noted, but also lower stock compensation due to performance measurement changes. Restructuring initiatives in 2023 involved severance and termination benefits, impacting some employees.

Next Steps

• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Continue efforts to optimize capital structure, potentially drawing on the Incremental Facility or exploring other financing sources.
• Manage the retirement of the 2025 Convertible Notes by October 15, 2025.
• Monitor and manage medical claims costs within the Performance Suite through contractual protections and clinical interventions.
• Integrate Machinify acquisition and manage its earn-out payments, with a portion due in Q4 2025.

Key Dates

Recommendation

The company's Q2 2025 results show a significant decline in revenue and a substantial increase in net loss, alongside negative operating cash flow. These are strong indicators of underperformance. However, the company is actively engaged in strategic financial maneuvers, including a major debt restructuring that converts preferred equity to a second lien term loan, which could simplify its capital structure and potentially reduce future dilution risk. The noted shift towards higher-margin product types in cost of revenue is a positive operational sign. Given the mixed signals – poor current financial performance but proactive strategic adjustments and some positive operational shifts – a 'hold' recommendation is appropriate. Investors should monitor the impact of the debt restructuring, the company's ability to manage industry-wide cost pressures, and its success in securing new revenue bookings for 2026.

Keywords

Healthcare Technology, Value-Based Care, Specialty Care Management, Health Plan Operations, Claims Processing, SEC Filing, 10-Q, Financial Results, Debt Restructuring, Convertible Notes, Second Lien Debt, Ares Capital Corporation, Machinify, Acquisition, Risk Management, Corporate Governance, Financial Performance, Medicaid Redeterminations, Medical Claims Costs, Liquidity